A Phase 2 interventional study of ETC-1002 and Placebo in Hyperlipidemia and Type 2 Diabetes, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.
Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 194th largest by enrollment of the 306 interventional ones that give a count, is one of 13 that started in 2012, is one of 43 in phase 2, and was the 156th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
Colorado Prevention Center · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
Cambridge Health Alliance · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 54 · Phase 3 77 · Phase 4 23
First in 1976; this study’s year is marked. 13 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 120 across the 306 interventional studies, 104 across the 29 observational. Of the 271 that completed or were terminated, 109 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 338 have an industry lead sponsor. The 10 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Esperion Therapeutics, Inc. has 9 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
20 of the studies in Hyperlipidemias with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT06062394University of PennsylvaniaPenn Medicine Healthy Heart | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 338 studies in Hyperlipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
Drug: ETC-1002
Placebo daily 4 weeks
Drug: Placebo
ETC-1002 Daily for 4 weeks
Placebo Daily for 4 weeks
assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes
evaluate the change in LDL-C from baseline to various time points
Time frame: 4 weeks
assess the effect of ETC-1002 versus placebo on glycemic parameters including fasting plasma and postprandial glucose and insulin
evaluate the change in glucose and insulin from baseline to various time points
Time frame: 4 weeks
assess the effect of ETC-1002 versus placebo on measures of insulin sensitivity in subjects with type 2 diabetes
evaluate the change in HOMA-IR from baseline to various time points
Time frame: 4 weeks
assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters
evaluate any changes in safety parameters during the course of the study.
Time frame: 4 weeks
The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid